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Abstract
　The p16, p15, and p14 genes are widely known as tumor suppressor genes in human medicine. Al-
though a large number of genetic and epigenetic aberrations in these genes have been reported in hu-
man malignancies, canine malignancies have not been well analyzed on the aberrations of these genes. In 
this study, the full-length complementary DNA （cDNA） of the canine p16 gene was cloned using the 5′ 
and 3′ rapid amplification of cDNA ends methods. Based on the sequence data, primers specific for p16, 
p15, and p14 were designed. Using these primers, the expression of p16, p15, and p14 mRNAs could be 
individually evaluated by reverse transcriptase polymerase chain reaction. Genomic aberrations were also 
examined using genomic polymerase chain reaction. Two of the 6 canine lymphoid tumor cell lines did 
not express detectable levels of p16, p15, and p14 mRNAs, and wide-ranging deletions in the p15-p14-p16 
genomic locus were suspected. Wide-ranging deletions were also speculated in 2 of 14 dogs with T-cell 
lymphoid tumors. On the other hand, similar failure of amplification suggesting wide-ranging deletions 
were not observed in any of the 14 dogs with B-cell lymphoma. Deletion of the p15-p14-p16 genomic lo-
cus could be one of the molecular aberrations in canine lymphoid tumor cells. 
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INTRODUCTION
　The p16, p15, and p14 genes are widely known as tu-
mor suppressor genes in human medicine8，11）. They are 
clustered in a region on human chromosome 9 corre-
sponding to mouse chromosome 4, and canine chromo-
some 119，41）. The P16 and P15 proteins belong to the in-
hibitor of cyclin-dependent kinase 4 （INK4） family, and 
are known as INK4a （cyclin-dependent kinase inhibitor 
2A ［CDKN2A］） and INK4b （CDKN2b）, respectively. By 
binding directly to CDK4 and CDK6, P16 and P15 block 
the formation of cyclin D-CDK complexes, resulting in 
the phosphorylation of retinoblastoma （RB） proteins and 
G1-phase cell cycle arrest. The p14 gene, which is also 
known as alternative reading frame （ARF）, regulates the 
cell cycle via an alternative pathway. By binding to the 
murine double minute 2 （MDM2） protein, P14 inhibits 
the degradation of P53 by MDM2. Because P53 induces 
G1-phase cell cycle arrest in conjunction with P21, the 
outcome of this pathway is similar to that of the P16 and 
P15 pathways. The human p16 and p14 genes are com-
posed of 3 exons each, and are known to share common 
exons 2 and 3.
　A large number of genetic and epigenetic aberrations 
of the p16, p15, and p14 genes have been reported in hu-
man malignancies. Of these 3 genes, inactivation of p16 
has been most frequently found in hematological malig-
nancies, such as lymphoma2，3，5，6，10，16，17，20，24，37，45）, leuke-
mia13，18，19，22，30，33，39，43）, and multiple myeloma25，32） as well as 
other non-hematological malignancies of various 
types25，32）. Inactivation of p16 results from 4 types of al-
terations, namely, homozygous deletion, promoter hyper-
methylation, loss of heterozygosity, and point mutations. 
Inactivation of p16, occurring mainly due to deletions 
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and methylations8）, was observed in 44% of hematological 
tumor patients40）. Furthermore, deletions of the 3 genes 
occur more frequently in patients with T-cell malignan-
cies than in those with B-cell malignancies8）. By contrast, 
patients with B-cell malignancies exhibit a higher inci-
dence of inhibition of expression due to hypermethyla-
tions8）.
　Partial or whole sequence data of the p16, p15, and 
p14 open reading frames have been reported. Four re-
ports on the canine p16 gene have been published7，9，21，27） 
since the identification of the partial sequence of its exon 
2 （GenBank accession no. FJ542309）21）. In another 
study1）, the entire coding sequence of the canine p15 
gene （GenBank accession no. NM_00114629） and partial 
sequence of the canine p14 gene （GenBank accession no. 
FM883643） were reported. However, the genomic locus 
harboring p16, p15, and p14 has not been thoroughly ex-
amined in dogs. The predicted canine p16, p15, and p14 
gene locus, deduced from the corresponding loci in other 
species, is shown in Fig. 1. Canine p16 and p14 genes are 
thought to share common exons 2 and 3, with a unique 
alternatively spliced first exon. Further, the previously 
reported partial sequence of canine p16 gene exon 2 ex-
hibited high homology to the sequence of p15 gene exon 
2. Therefore, the primers designed to amplify exon 2 of 
the canine p16 gene in previous studies7，9，21，27） would also 
amplify the p15 and p14 genes. To examine the expres-
sion of p16, p15, and p14 independently, it would be nec-
essary to determine the whole sequence of exon 1 of the 
canine p16 gene. 
　Using primers that would amplify not only p16 but 
also p15 and p14, 2 previous studies reported low or un-
detectable expression of these 3 genes in canine lympho-
ma9，27）. Partial loss of chromosome 11, on which these 
genes are located, has also been reported in canine lym-
phoid malignancies using fluorescent in situ hybridization 
analysis and comparative genomic hybridization9，12，41）. 
Based on these reports, the p16, p15, and p14 genes are 
speculated to be partially or completely deleted in canine 
lymphoid malignancies, similar to human lymphoid tu-
mors.
　The first purpose of this study was to determine the 
complete nucleotide sequence of the canine p16 cDNA, 
in order to design primers specific to p16, p15, and p14. 
The second purpose was to examine the aberration of 
the p16, p15, and p14 genes in the canine lymphoid tu-
mor cell lines and primary tumor cells from dogs with 
various lymphoid tumors.
MATERIALS AND METHODS
　Cells and patient samples: Six lymphoid tumor cell 
lines derived from dogs with naturally occurring lym-
phoid malignancies were examined. These included 
CLBL-1 （multicentric B-cell lymphoma）35）, GL-1 （B-cell 
acute lymphoblastic leukemia ［ALL］）29）, UL-1 （renal 
T-cell lymphoma）44）, CL-1 （mediastinal T-cell lympho-
ma）28）, Nody-1 （alimentary T-cell lymphoma）15）, and Ema 
（mediastinal T-cell lymphoma）15）. Four of these cell lines 
（CLBL-1, GL-1, UL-1, and CL-1） were cultivated in RPMI-
1640 （Invitrogen, Grand Island, NY） supplemented with 
10% fetal bovine serum （Biowest, Nuaillè, France）, peni-
cillin （100 units/ml）, and streptomycin （0.1 mg/ml） （Sig-
ma-Aldrich, St. Louis, MO）. The other 2 cell lines （Nody-
1, Ema） were cultivated in RPMI-1640 supplemented 
with 20% fetal bovine serum （Nichirei Biosciences Inc., 
Tokyo, Japan）, penicillin （100 units/ml）, and streptomy-
cin （0.1 mg/ml）. All cell lines were maintained in an at-
mosphere of 5 % CO2. 
　Lymph node （LN） cells were obtained as a control 
from a healthy dog kept for blood transfusion in our 
teaching hospital via fine-needle aspiration （FNA）. The 
dog was kept in accordance with the guidelines of Ani-
mal Care Committee of the Graduate School of Agricul-
tural and Life Sciences, the University of Tokyo.
　Dogs with lymphoid tumors were cytologically or 
pathologically diagnosed. Furthermore, clonal rearrange-
ment of the immunoglobulin heavy chain （IgH） gene or 
the T-cell receptor gamma chain （TCRγ） gene in tumor 
cells confirmed using previously described primers4，42） 
was examined to indicate their clonal origin and B- or 
T-cell linage. Fourteen dogs （dogs nos. 1–14） with IgH 
rearrangement were included and all were diagnosed 
Fig. 1．　 Predicted gene locus of the p16, p15, and p14 
genes on canine chromosome 11 deduced from 
the gene locus on human chromosome 9. The 
identified and unidentified exons of p16, p15, and 
p14 are indicated by white and black squares, 
respectively. Arrow with asterisk （*） indicates a 
gap in canine genome database. Location of the 
primers in exon 2 of p16 used in previous 
studies21） are indicated by daggers （†）.
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with multicentric high-grade lymphoma. Primary tumor 
cell samples were obtained from the LN of these dogs by 
FNA. Of the other 14 dogs （dogs nos. 15–28） showing 
TCRγ rearrangement, 11 dogs were diagnosed as hav-
ing alimentary lymphoma, 1 with ALL, and 2 with chron-
ic lymphocytic leukemia （CLL）. Primary tumor cell sam-
ples were obtained by endoscopy from dogs with the 
alimentary lymphoma, and by peripheral blood mononu-
clear cell （PBMC） separation by gradient centrifuga-
tion44） from the dogs with ALL and CLL. All primary tu-
mor samples were obtained with owners’ informed 
consent.
　Full-length cloning of canine p16 complementary DNA: 
Total RNA was isolated using Illustra RNA Spin Mini 
（GE Healthcare, Little Chalfont, Buckinghamshire, UK）, 
followed by DNase I （Invitrogen） treatment. Compli-
mentary DNA （cDNA） was synthesized using PrimeS-
cript® RT reagent Kit （TakaraBio, Shiga, Japan）. All 
protocols were performed in accordance with the manu-
facturer’s instructions. To amplify a part of exon 1 of ca-
nine p16, we designed degenerative primers, p16 EX-
ON-F94 and p16 EXON-R293 （Table 1）, based on the 
sequence of p16 exon 1 from other species （human, 
chimpanzee, cattle, mouse, and rat）. PCR amplification 
was performed with AmpliTaq gold® 360 （Applied Bio-
systems, Grand Island, NY） using normal LN cDNA as 
template. Cycle conditions included an initial denatur-
ation step at 95℃ for 10 min, followed by 35 cycles of de-
naturation at 95℃ for 3 s, annealing at 68℃ for 30 s, and 
extension at 72℃ for 60 s, with a final extension step at 
72 ℃ for 7 min. The PCR amplification products were 
electrophoresed on 2% agarose gel （BMBio, Tokyo, Ja-
pan）, purified using Wizard® SV Gel and PCR Clean-Up 
System （Promega, Madison, WI）, and inserted into the 
pGEM®–T Easy Vector System （Promega）. After trans-
formation, plasmid DNA was extracted using Nucle-
oSpin® Plasmid QuickPure （Macherey-Nagel, Düren, 
Germany） and subjected to sequence analysis using Big-
Dye® Terminator v3.1 Cycle Sequencing Kit （Applied 
Biosystems） and 3130xl Genetic Analyzer （Applied Bio-
systems）.
　The 5′ Rapid amplification of cDNA ends （ 5 ′ RACE） 
method was used to determine the full-length sequence 
of exon 1 of the p16 gene using 5′-full RACE Core Set 
（TakaraBio）. CL-1 cDNA template was generated using 
the p16 EXON2-R1481 primer phosphorylated at the 5′ 
end. After circularization using T4 ligase, the cDNA was 
amplified by nested-PCR using 4 primers： p16 EX-
ON2-F1374 and p16EXON2-F1411, and p16 EXON 1-R169 
and p16 EXON 1-R146 （Table 1）. Three primers, p16 
Table 1．　 Primer sequences used for full-length complementary DNA cloning and expression analysis of 
the p16 gene in this study
Primer name Primer sequence （5’-3’） Genbank no., nucleotide number Amplicon size （bp）
p16 EXON-F94 GASGTGCGGGCRCTGCTSG AB675384, nt. 94-112
200
p16 EXON-R293 GTGTCCAGGAAGCCCTCCCG AB675384, nt. 293-274 
p16 EXON2-R1481 P-CAACTCAGATGTGGC FM883643, nt. 1481-1466
NA
p16 EXON1-R169 ATGACCTGAATCGGGCTCCGA AB675384, nt. 169-150
p16 EXON1-R146 AGGCGGTTCGGCGCGTCGGGA AB675384, nt. 146-126
p16 EXON2-F1374 GCTGTCGCTGCGTACCTGCG FM883643, nt. 1374-1385 
p16 EXON2-F1411 CCGAAAGTGGTAGCCACGCC FM883643, nt. 1411-1430 
p16 EXON2-F153 GAGCCCGATTCAGGTCAT AB675384, nt. 153-170 
p16 EXON1-F148 GGTCGGAGCCCGATTCA AB675384, nt. 148-169
95
p16 EXON1-R242 ACGGGGTCGGCACAGTT AB675384, nt. 242-226
RPL13A-F GCCGGAAGGTTGTAGTCGT AJ388525, nt. 87-105
87
RPL13A-R GGAGGAAGGCCAGGTAATTC AJ388525, nt. 173-154
p15 EXON1-F90 GCGGCAGCTCCTGGAAG NM_00114629, nt. 90-106
140
p15 EXON1-R230 GGGTCGGCACAGTTGG NM_00114629, nt. 230-215 
p14 EXON1-F330 GCCCTGGTGCTAAAGCTAGT FM883643, nt. 330-349
154
p14 EXON1-R1230 TGACGGGGTCGGCACAGTT FM883643, nt. 1230-1212
GAPDH-F TCACCAGGGCTGCTTTTAAC AB038240, nt. 47-67
403
GAPDH-R AGGAGGCATTGCTGACAATC AB038240, nt. 448-429
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase； NA, not applicable （primers used for 5’ and 3’ RACE）； P, 
Phosphate group； R represents A or G, S represents C or G
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EXON2-R1481,  p16 EXON2-F1374,  and p16 EX-
ON-2F1411, were designed on the basis of the exon 2 se-
quences of the p16/p14 genes in GenBank （GenBank ac-
cession no. FM883643）； the other 2 primers, p16 
EXON1-R169 and p16 EXON1-R146, were designed on 
the basis of the partial sequence of p16 exon 1 deter-
mined in this study （fragment amplified with p16 EX-
ON-F94 and p16 EXON-R293 primers） （GenBank acces-
sion no. AB675384）. Both the first and second PCR 
amplifications were performed using Takara LA Taq 
with GC Buffer （TakaraBio）. Cycle conditions included 
an initial denaturation step at 94℃ for 1 min, followed by 
25 cycles of denaturation at 94 ℃ for 30 s, annealing at 
62℃ for 30 s, and extension at 72℃ for 60 s, with a final 
extension step at 72℃ for 5 min. The PCR product was 
cloned and sequenced as described above.
　The 3′ RACE method was used to determine the uni-
versal exon 3 of the p16/p14 genes using 3′-full RACE 
Core Set （TakaraBio）. A primer, p16 EXON2-F153, was 
designed on exon 2 of the p16/p14 genes （Table 1）. The 
first strand of cDNA was synthesized from CL-1 RNA 
using oligo-dT primer containing an adaptor sequence. 
Subsequent PCR amplification was performed with the 
p16 EXON2-F153 primer and a supplied primer comple-
mentary to the adaptor sequence using AmpliTaq gold® 
360. The protocol consisted of an initial denaturation step 
at 95℃ for 10 min, followed by 35 cycles of denaturation 
at 95℃ for 3 s, annealing at 60℃ for 35 s, and extension 
at 72℃ for 60 s, with a final extension step at 72℃ for 7 
min. The PCR amplification product was cloned and se-
quenced as described above.
　Real-time PCR analysis of p16 expression in canine 
lymphoid tumor cell lines: The primers p16 EXON1-F148 
and p16 EXON1-R242 were designed to amplify 95 base 
pairs （bp） of p16 exon 1 based on the p16 sequence de-
termined in this study （Table 1）. The mRNA expression 
in each cell line was measured by real-time PCR using 
SYBR® Premix Ex Taq （TakaraBio）. Ribosomal protein 
L13A （RPL13A） was used as the endogenous control 
（RPL13A F and RPL13A R； amplicon length 87 bp, Ta-
ble 1）. The cycle protocol was as follows： denaturation 
step at 95℃ for 10 s； 40 cycles of denaturation at 95℃ 
for 5 s, and annealing/extension at 60 ℃ for 30 s； fol-
lowed by the dissociation step at 95℃ for 5 s, 60℃ for 30 
s, and 95 ℃ for 15 s. The PCR amplicons were electro-
phoresed on 12.5% polyacrylamide gel （ATTO, Tokyo, 
Japan）. 
　The comparative cycle threshold （Ct） method was 
used to quantify p16 transcript levels. ΔCt was deter-
mined by subtracting the Ct value of RPL13A from the 
Ct value of the p16 gene. ΔΔCt was calculated by sub-
tracting the ΔCt of the control sample from the ΔCt of 
the target sample. Normal LN was used as the control 
sample in this study. The levels of the p16 transcripts 
relative to that in the normal LN was calculated as 2-ΔΔCt. 
To confirm the amplification efficacy of the primers, a 
standard curve was generated using serial dilutions of 
the CL-1 cDNA as template. All samples were evaluated 
in triplicate. 
　Expression analysis of the p15 and p14 genes in canine 
lymphoid tumor cell lines: Primers specific for p15, p15 
EXON1-F90 and p15 EXON1-R230, and p14, p14 EX-
ON1-F330 and p14 EXON1-R1230, were designed based 
on the sequences of p15 and p14 registered in GenBank 
（accession nos. NM_00114629 and FM883643）, respec-
tively （Table 1）. GAPDH was used as the endogenous 
control gene （primers GAPDH-F and GAPDH-R； Table 
1）. Reverse transcriptase-polymerase chain reaction （RT-
PCR） amplification was performed for the p15 and p14 
genes using  AmpliTaq gold® 360 and the cDNAs of the 
cell lines as templates in the following protocol： initial 
denaturation at 95℃ for 10 min, followed by 35 cycles of 
denaturation at 95℃ for 3 s, annealing at 60℃ for 30 s, 
and extension at 72℃ for 60 s, with a final extension step 
at 72℃ for 7 min. The PCR amplification products were 
electrophoresed on 12.5% polyacrylamide gel.
　Amplification of the p15-p14-p16 gene locus on chromo-
some 11 by genomic PCR: Genomic DNA was extracted 
using QIAmp DNA Mini kit （Qiagen, Hilden, Germany）. 
Eight pairs of primers （Table 2） covering a 100-kb re-
gion of canine chromosome 11, including the introns and 
exons of the p16, p15, and p14 genes, were designed 
（Fig. 2）. The primer sequences are listed in Table 2. The 
GAPDH gene was used as the endogenous control. PCR 
amplification was performed using AmpliTaq gold® 360 
and the DNAs of cell lines and patient samples as tem-
plates. The PCR protocol was as follows： initial denatur-
ation at 95℃ for 10 min, followed by 35 cycles with dena-
turation at 95℃ for 3 s, annealing at 60℃ for 30 s, and 
extension at 72℃ for 60 s, with a final extension step at 
72 ℃ for 7 min. Electrophoresis was performed on 2% 
agarose gel. Amplification using distilled water was re-
garded as negative control.
RESULTS
　Full-length cloning of canine p16 cDNA: Using 5 ′ 
RACE and 3 ′ RACE methods, the nucleotide sequence 
of full-length canine p16 cDNA was determined. A 705 –
bp entire open reading frame encoding 151 amino acids 
could be identified （GenBank accession no. AB675384, 
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nucleotide ［nt］ 40–492）. In the dog genome database, nt 
no. 166–472 and nt no. 473–705 of canine p16 cDNA were 
found on canine chromosome 11 separately using BLAST 
（National Center for Biotechnology Information, Bethes-
da, MD） （nt no.166-472, 32195005–32195311； nt no. 473–
705, 32192558–32192790）. However, no sequence corre-
sponding to the 5′ fragment of canine p16 （nt no. 1–165） 
was found in the dog genome database. Because there is 
a gap region between exon 1β of the p14 gene and exon 
2 of the p16/p14 genes where its exon 1α is expected to 
be locate （Fig. 1, 2） in the dog genome database, the 5′ 
fragment of canine p16 （nt no. 1–165） was expected to 
be locate in this region. Nt no. 1–165 of canine p16 was 
considered to be its exon 1α, and nt no. 166–472 and nt 
no. 473–705 were regarded as its exons 2 and 3 from the 
result of the alignment of the sequence （nt no.166–705） 
of canine p16 cDNA using BLAST. Therefore, canine 
p16 gene was assumed to be composed of 3 exons.
Fig. 2．　 Locations for the genomic PCR amplification on the p15-p14-p16 gene locus. Arrow with asterisk （*） indicates 
a gap in the canine genome database. Black bars at the bottom represent the regions amplified by 8 primer 
pairs.
Table 2．　Primer sequences used to amplify the p15-p14-p16 genomic locus in this study
Primer name Primer sequence (5'-3') Genbank no., nucleotide number Amplicon size (bp)
p15 usEXON1-F1 TGCCCTAACATTAATTTCTTCTCAG AAEX02016331.1, nt. 54947-54971
399
p15 usEXON1-R1 GACCTTTGACCAGAATGAAGAGATA AAEX02016331.1, nt. 54777-54753
p15 usEXON1-F2 GGACATGTAATTTGAACCCAGATAG AAEX02016331.1, nt. 44716-44740 
303
p15 usEXON1-R2 TCCTAATCTCCCTTCCTAGACACTT AAEX02016331.1, nt. 44462-44438 
p16 dsEXON3-F CACCTTGTGGGAACTCTAGAAAGTA AAEX02016329.1, nt. 1182-1206 
529
p16 dsEXON3-R TATTCAAAAGGGGTATTGGTCTGTA AAEX02016329.1, nt. 802-778
p15 usEXON1-F GAAGAGGGCTGAAAGCTGACCT AAEX02016331.1, nt. 13506-13522 
561
p15 dsEXON1-R CCAAACTTAAGTAGCGTTTGTTGTT AAEX02016331.1, nt. 12984-12962 
p15 usEXON2-F ATCAACAAAGTATAACGGACTCCTG AAEX02016331.1, nt. 10872-10896 
500
p15 dsEXON2-R ACATTTGTAGCCTCCCTTCAACT AAEX02016331.1, nt. 10169-10146 
p16 dsEXON1-F CTCTCAAAATCCCTTCACACTTAAA AAEX02016329.1, nt. 9417-9441 
529
p16 dsEXON1-R CTACCATTTTGAGGGTACCTCCTAT AAEX02016329.1, nt. 8937-8913 
p16 dsEXON2-F GTCATGATGATGGGCAGCACCCGCGT AAEX02016329.1, nt. 7139-7164 
1093
p16 dsEXON2-R AATGGTTCTCCCTTCAGAAAAAG AAEX02016329.1, nt. 6095-6072 
p16 usEXON3-F TGAGGTGCCACATCTGAGTT AAEX02016329.1, nt. 6831-6856 
2600
p16 usEXON3-R CAAGCATGCAGGGAAGAGTT AAEX02016329.1, nt. 4555-4534
GAPDHgen-F TCACCAGGGCTGCTTTTAAC AB038240, nt. 47-67
818
GAPDHgen-R AGGAGGCATTGCTGACAATC AB038240, nt. 448-429
GAPDH, Glyceraldehyde-3-phosphate  dehydrogenase; R, Reverse
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　The determined full-length cDNA sequence and the 
deduced amino acid sequence of canine p16 were com-
pared with those of other species. The cDNA sequence 
of the coding region shared 85%, 86%, 86%, 79%, and 76% 
identities with human, chimpanzee, cattle, mouse, and rat 
sequences, respectively. The deduced amino acid se-
quence of canine p16 was 81%, 81%, 82%, 61%, and 76% 
homologous to that of human, chimpanzee, cattle, mouse, 
and rat, respectively （Fig. 3）. Exons 1 and 2 of canine 
p16 were shown to contain 4 ankyrin repeats highly con-
served among various species34）.
　Expression analysis of p16, p15, and p14 genes using 
real-time RT-PCR or RT-PCR: The levels of p16 mRNA 
were determined using real-time RT-PCR. The levels of 
p16 mRNA in CLBL-1 and GL-1 cells were lower than 
that in normal LN cells, and below the limit of detection 
in UL-1, Nody-1, and Ema cells. The amount of p16 
mRNA in CL-1 was approximately 100 fold higher than 
that in normal LN cells （Fig. 4）. Further, the levels of 
p15 and p14 expression were examined using RT-PCR. 
The levels of p15 and p14 mRNAs were uniformly high 
in 4 cell lines （CLBL-1, GL-1, UL-1, and CL-1） compared 
to that in normal LN cells. On the other hand, expression 
of p15 and p14 mRNAs was below the limit of detection 
in Nody-1 and Ema cells （Fig. 5）. Amplification was not 
observed in these 2 cell lines even when the number of 
PCR cycles was increased from 35 to 40 （data not 
shown）.
　Amplification of the p15-p14-p16 gene locus by genomic 
PCR: To examine deletion in the genomic locus of p16, 
p15, and p14 genes, we designed 8 primer pairs to ampli-
fy each region of the locus （Fig. 2）. All the 8 primer 
pairs designed in the locus amplified the fragments of 
expected sizes in 4 cell lines （CLBL-1, GL-1, UL-1, and 
Fig. 3．　 Amino acid sequence comparison of the deduced canine P16 with P16 of human （GenBank accession no. 
NM_000077.3）, chimpanzee （GenBank accession no. NM_001146290.1）, cattle （GenBank accession no. 
XM_868375.4）, mouse （GenBank accession no. NM_009877.2）, and rat （GenBank accession no. NM_031550）. 
The corresponding exons are indicated below the sequence. Dash denotes gap.
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CL-1） and LN cells, whereas no amplification was ob-
served with any of the 8 primer pairs in Nody-1 and 
Ema cells （Fig. 6）. 
　 Primary lymphoid tumor samples were also examined 
by genomic PCR. Due to limited DNA samples from lym-
phoid tumor patients, 5 primer pairs covering the exon 
regions of p16, p15, and p14 were used to examine each 
gene loci. Faint bands were presumed to arise from 
non-tumor cells derived from the surrounding normal tis-
sues.
　The 14 dogs diagnosed with multicentric high-grade 
lymphoma and harboring clonal IgH gene rearrange-
ments all exhibited amplifications products of the expect-
ed sizes in the regions p15 EXON1, p16 dsEXON2, and 
p16 usEXON3 （Fig. 7）. Amplified bands corresponding 
to p15 EXON2 and p16 dsEXON1 were faint to absent in 
2 （dog nos. 4 and 9） and 1 （dog no. 7） of the 14 dogs, re-
spectively. Eleven dogs showed successful amplifications 
with all the 5 primer pairs.
　Among the 14 dogs with clonal TCRγ gene rearrange-
ments （alimentary lymphoma, ALL, and CLL）, amplifica-
tions of region p15 EXON1, p15 EXON2, p16 dsEXON1, 
p16 dsEXON2, and p16 usEXON3 were faint to absent in 
2 （dog nos. 15 and 23）, 3 （dog nos. 15, 18, and 23）, 5 （dog 
nos. 15, 18, 19, 20, and 23）, 2 （dog nos. 15, and 23）, and 2 
（dog nos. 15, and 23） dogs, respectively （Fig. 7）. In 2 
dogs （dog nos. 15 and 23）, no or faint bands were detect-
ed with any of the 5 primer pairs. The results of genom-
ic PCR in primary lymphoid tumor samples were sum-
marized in Table 3.
DISCUSSION
　In this study, we identified the full-length nucleotide 
sequence of the canine p16 gene. As expected, canine 
p16 was composed of 3 exons, sharing exons 2 and 3 
with the p14 gene. The deduced canine p16 amino acid 
sequence was highly homologous to that of human, chim-
panzee, and cattle throughout the coding region. On the 
Fig. 4．　 Expression analysis of the p16 gene in canine 
lymphoid tumor cell lines and a lymph node 
tissue using real-time polymerase chain reaction 
（RT-PCR）. Levels of p16 mRNA were measured 
relative to that in normal LN tissue as a control 
sample. The expression of p16 mRNA is below 
the detection limit in UL-1, Nody-1, and Ema. 
Data are expressed as the mean value of 
triplicate assay. 
Fig. 5．　 Expression analysis of the p15 and p14 genes in 
canine lymphoid tumor cell lines and a lymph 
node tissue using RT-PCR. Thirty-five cycles of 
PCR reaction was performed for each gene. 
GAPDH （glyceraldehyde- 3 -phosphate dehydroge-
nase） was used as a control. 
Fig. 6．　 Genomic  PCR amp l i f i c a t i on  o f  r eg i on s 
corresponding to the p15-p14-p16 gene locus on 
chromosome 11. The location of each region is 
shown in Fig. 2. GAPDH gene was used as a 
control. 
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other hand, the exon 3 sequence exhibited limited identi-
ty with that of mouse and rat, although exons 1 and 2 
were relatively conserved. Exons 1 and 2 contained 4 
ankyrin repeats, which are known to be highly con-
served among various species34）. The ankyrin repeat mo-
tif may be important for maintaining the functional con-
formation of P16.
　The cloning of p16 exon 1 enabled us to design prim-
ers that distinguished p16 from p15 and p14. Although 
exon 2 of p15 and p16/p14 were highly homologous, 
exon 1 of each gene shared only limited identity, and 
therefore it was possible to design primers specific to 
each gene. However, the primers specific for p15 and 
p14 generated several non-specific products, and could 
not be used for quantification. It was difficult to design 
another primer for p15 because of the high homology of 
its exon 2 with that of the p16/p14 genes （98%）. Fur-
ther, polymorphism in exon 1 of the p15 gene was re-
ported in normal dogs1）. Indeed, the reported polymor-
phism in p15 exon 1 was also observed in CLBL-1, GL-1, 
UL-1, CL-1, and LN tissues by sequence analysis （data 
not shown）. Therefore, we did not quantify p15 expres-
sion by real-time RT-PCR.
　In this study, a part of the p16 nucleotide sequence 
（GenBank accession no. AB675384, nt 1–91） was obtained 
from CL-1 cells but not confirmed in normal cells. Be-
cause p16 expression was low in normal cells39，46）, it was 
difficult to obtain a clear band from normal tissue by RT-
PCR and 5 ′ RACE. Instead, CL-1 cDNA was used as a 
template for PCR because this cell line exhibited remark-
ably high expression of the p16 gene. Further, it was not 
possible to verify the sequence from the genome data-
Fig. 7．　 Genomic PCR amplification for the p15-p14-p16 gene locus in 28 canine primary tumor samples. The location 
of each region is shown in Figure 2. Band intensities fainter than that of normal LN were considered as 
absence of amplification. Dogs 1 –14 were diagnosed as having multicentric high-grade lymphoma with clonal 
immunoglobulin heavy chain gene rearrangement. Dogs 15–25 were diagnosed with alimentary lymphoma, dog 
26 with acute lymphoblastic leukemia （ALL）, and dogs 27 and 28 with chronic lymphocytic leukemia （CLL）. 
Dogs 15–28 exhibited clonal T-cell receptor gamma chain gene rearrangements. Genomic DNA purified from 
normal LN tissue and peripheral blood mononuclear cell （PBMC） was used as controls. The result of PBMC 
was similar to that of LN （data not shown）. Amplification using distilled water was regarded as negative 
control.
Table 3．　Results of genomic PCR to amplify the p15-p14-p16 locus in primary lymphoid tumor samples
Dogs No.
Multicentric high-grade lymphoma Alimentary lymphoma ALL CLL
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
p15 EXON 1 ＋ + + + + + + + + + + + + + － + + + + + + + ± + + + + +
p15 EXON 2 + + + ± + + + + ± + + + + + － + + － + + + + ± + + + + +
p16 ds EXON 1 + + + + + + － + + + + + + + － + + － － ± + + － + + + + +
p16 ds EXON 2 + + + + + + + + + + + + + + － + + + + + + + ± + + + + +
p16 us EXON 3 + + + + + + + + + + + + + + － + + + + + + + － + + + + +
ALL, acute lymphoblastic leukemia； CLL, chronic lymphocytic leukemia； +, distinct band； ±, faint band； －, no band
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base because p16 exon 1α is located in the gap region. 
The remaining part of the p16 gene （nt 92–705） was 
identical between normal LN and CL-1 cells. Although 
the sequence of 5 ′ end of canine p16 cDNA should be 
verified in normal LN cells, the data gathered in this 
study conceivably reflected the sequence of canine nor-
mal p16 cDNA.
　The amount of p16 mRNA expression was smaller in 5 
（B-cell lines； CLBL-1 and GL-1, and 3 T-cell lines； UL-1, 
Nody-1, and Ema） of the 6 canine lymphoid tumor cell 
lines, compared to that in normal LN cells. p15 and p14 
mRNAs were also undetectable in 2 lymphoid tumor cell 
lines （Nody-1 and Ema）. On the other hand, p16 mRNA 
was highly expressed in CL-1 （T-cell line）. It has been 
reported that RB protein becomes inactivated when it is 
excessively phosphorylated, which elicits high expression 
of p16 mRNA due to a feedback mechanism14，26，31）. Ex-
amination of the phosphorylation status of RB in CL-1 
cells will be needed. Furthermore, when some of the cell 
cycle regulators such as p21, p27, p57, and p53 are inacti-
vated and the progression of cell cycle occurs, over ex-
pression of p16 mRNA could be induced as a feedback 
mechanism. Since mediastinal lymphoma is very rare in 
dogs, we did not have an opportunity to examine the p16 
mRNA expression level in primary tumor samples from 
dogs with mediastinal lymphoma. In previous studies on 
the prognosis of canine lymphoma38）, the presence of me-
diastinal mass was shown as a poor prognostic factor. 
Further study is needed to examine the relationship be-
tween the augmented p16 expression and the disease 
type or the biologic behavior of lymphoid tumors in dogs. 
　In Nody-1 and Ema, p16, p15, and p14 mRNAs were 
not detected. Furthermore, genomic PCR amplification 
for the p15-p14-p16 locus of the DNA samples with the 8 
primer pairs did not generate any product in locus in 
Nody-1 and Ema. These results suggest the presence of 
wide-ranging deletions in chromosome 11 in Nody-1 and 
Ema. To confirm the exact status of the genetic deletions 
in these 2 cell lines, Southern blot analysis would be nec-
essary. In the cells with such wide-ranging deletion, 
there should be a simultaneous loss of p16, p15, and p14 
resulting in the failure of cell cycle control. Inactivation 
of these genes, especially in their combinations, was im-
plicated in the tumorigenesis and malignancy from the 
studies of the in vitro and in vivo mouse model systems 
with targeted disruption of the corresponding genes23）. 
Induction of wild-type p16 into p16-deficient human lym-
phoma cell lines leads to growth retardation and partial 
differentiation, indicating that p16 deficiency might con-
tribute to the malignant phenotype23）. Mice with targeted 
disruption of both p16/p19 loci developed lymphomas 
and lymphoid leukemias with a low penetrance, as well 
as other tumors36） From these findings, the simultaneous 
inactivation of p16, p15, and p14 genes would be also as-
sociated with the tumorigenesis and malignancy in ca-
nine T-lymphoid tumor cells. 
　The amounts of p16 mRNA in CLBL-1, GL-1, and UL-1 
were shown to be lower than that in normal LN, where-
as those of p15 and p14 mRNAs in these cell lines were 
similar to that in normal LN. If only the amount of p16 
mRNA is decreased despite the presence of p15 and p14 
mRNAs as shown in normal LN, there is a possibility 
that deletion around p16 gene exon 1 exists without 
wide-ranging deletion over p15-p14-p16 locus. However, 
PCR amplification for the p16 gene exon 1 generated a 
distinct band in these 3 cell lines using genomic PCR. It 
is possible that genetic aberrations exist in p16 gene al-
though not detected in this study, or epigenetic mecha-
nism to suppress its expression might be related in these 
3 cell lines. 
　We further examined whether genetic aberrations sim-
ilar to that in Nody-1 and Ema exist in naturally occur-
ring canine lymphoid tumor cases. Similar failure of am-
plification of the p15-p14-p16 locus （p15EXON1, 
p15EXON2, p16dsEXON1, p16dsEXON2, and p16usEX-
ON3） was observed in 2 dogs （dog nos. 15 and 23） with 
T-cell alimentary lymphoma, although several faint bands 
conceivably derived from concomitant normal cells were 
observed in dog no. 23. Such failure of amplification was 
not observed in any of the 14 multicentric B-cell lympho-
ma dogs. 
　Thomas et al.41） indicated the frequent DNA copy 
number losses in p15-p14-p16 locus of chromosome 11 in 
canine T-cell lymphomas but not in B-cell malignancies, 
using array-based comparative genomic hybridization. 
Although further studies are needed, deletion of p15-
p14-p16 locus would be an important candidate to under-
stand the tumorigenesis in a subtype （possibly high-
grade T-cell lymphoma） of canine lymphoid tumors.
　Failure of amplification suggesting wide-ranging dele-
tion of p15-p14-p16 locus was observed in 2 canine lym-
phoid tumor cell lines, Nody-1 and Ema. Nody-1 was es-
tablished from tumor cells obtained from a patient with 
alimentary lymphoma 15）. Furthermore, similar failure of 
amplification was observed in 2 dogs （dog nos. 15 and 
23） with alimentary lymphoma. Thus, such aberration of 
p15-p14-p16 locus might be a type of genetic changes ob-
served in canine alimentary lymphoma. 
　On the other hand, 6 of 28 primary lymphoid tumor 
samples exhibited faint amplification failure with only 1 
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or 2 of the 8 primer pairs （B-cell lymphoid tumor nos. 4, 
7 and 9； T-cell lymphoid tumor nos. 18, 19, and 20） in 
this study, suggesting a different genetic aberration than 
in the tumor nos. 15 and 23. Failures of amplification 
could occur if mutation, single nucleotide polymorphisms 
at the primer-binding region, or heterozygous genetic de-
letion is present. Southern blotting or array comparative 
genomic hybridization would be required to reveal the 
cause of the failure of amplification. 
　In conclusion, the full-length canine p16 cDNA was 
cloned and the levels of p16, p15, and p14 expression in 
canine lymphoid tumor cell lines were determined. Fail-
ure of amplification suggesting wide-ranging deletions 
were observed in 2 canine T-cell lymphoid tumor cell 
lines lacking p16, p15, and p14 expression. Similar failure 
of amplification was also found in 2 primary tumor sam-
ples from alimentary T-cell lymphoma. Deletion of the 
p15-p14-p16 genomic locus could be one of the molecular 
aberrations in canine lymphoid tumor cells.
ACKNOWLEDGMENTS
　The authors would like to acknowledge Dr. Barbara C. 
Rütgen, Institute of Immunology, Department of Pathobi-
ology, University of Veterinary Medicine Vienna, for pro-
viding a canine lymphoma cell line （CLBL-1） and Dr. 
Takuya Mizuno, Laboratory of Veterinary Internal Medi-
cine, Faculty of Agriculture, Yamaguchi University, for 
providing 2 canine lymphoma cell lines （Nody-1 and 
Ema）. This study was supported by the Japan Society 
for the Promotion of Science, KAKENHI 24658265.
REFERENCES
 1） agUirre-Hernandez, j., milne, b. s., qUeen, C., 
o’brien, P. C., HoatHer, t., HaUgland, s., FergU-
son-smitH, m. a., dobson, j. m. and sargan, D. R. 
2009. Disruption of chromosome 11 in canine fibro-
sarcomas highlights an unusual variability of CD-
KN2B in dogs. BMC Vet. Res. 5：27.
 2） amara, k., trimeCHe, m., ziadi, s., laatiri, a., 
HaCHana, m. and korbi, s. 2008. Prognostic signifi-
cance of aberrant promoter hypermethylation of 
CpG islands in patients with diffuse large B-cell 
lymphomas. Ann. Oncol. 19： 1774–1786.
 3） baUr, a. s., sHaW, P., bUrri, n., delaCretaz, F., bos-
man, F. t. and CHaUbert, P. 1999. Frequent meth-
ylation silencing of p15（INK4b） （MTS2） and p16
（INK4a） （MTS1） in B-cell and T-cell lymphomas. 
Blood 94：1773–1781.
 4） bUrnett, r. C., vernaU, W., modiano, j. F., olver, C. 
s., moore, P. F. and averY, a. C. 2003. Diagnosis of 
canine lymphoid neoplasia using clonal rearrange-
ments of antigen receptor genes. Vet. Pathol. 40：
32–41.
 5） CHeUng, H. H., lee, t. l., rennert, o. m. and CHan, 
W. Y. 2009. DNA methylation of cancer genome. 
Birth Defects Res. C Embryo Today 87：335–350.
 6） CHU, l. C., eberHart, C. g., grossman, s. a. and 
Herman, J. G. 2006. Epigenetic silencing of multiple 
genes in primary CNS lymphoma. Int. J. Cancer 
119：2487–2491.
 7） deinnoCentes, P., agarWal, P. and bird, R. C. 2009. 
Phenotype-rescue of cyclin-dependent kinase in-
hibitor p16/INK4A defects in a spontaneous ca-
nine cell model of breast cancer. J. Cell. Biochem. 
106：491–505.
 8） drexler, H. G. 1998. Review of alterations of the 
cyclin-dependent kinase inhibitor INK4 family 
genes p15, p16, p18 and p19 in human leuke-
mia-lymphoma cells. Leukemia 12：845–859.
 9） Fosmire, s. P., tHomas, r., jUbala, C. m., Wo-
jCieszYn, j. W., valli, v. e., getzY, d. m., smitH, t. 
l., gardner, l. a., ritt, m. g., bell, j. s., Freeman, 
k. P., greenField, b. e., lana, s. e., kissebertH, W. 
C., HelFand, s. C., CUtter, g. r., breen, m. and mo-
diano, J. F. 2007. Inactivation of the p16 cyclin-de-
pendent kinase inhibitor in high-grade canine 
non-Hodgkin’s T-cell lymphoma. Vet. Pathol. 44：
467–478.
 10） garCia, m. j., Castrillo, j. m., granizo, j. j., Cazor-
la, a. and rivas, C. 2002. Clinicopathological cor-
relation, p16-p15 methylation status and outcome 
predictors in anaplastic large cell lymphoma. Br. J. 
Haematol. 119：877–878.
 11） gil, j. and Peters, G. 2006. Regulation of the 
INK4b-ARF-INK4a tumour suppressor locus： all 
for one or one for all. Nat. Rev. Mol. Cell Biol. 7： 
667–677.
 12） HaHn, k. a., riCHardson, r. C., HaHn, e. a. and 
CHrisman, C. L. 1994. Diagnostic and prognostic im-
portance of chromosomal aberrations identified in 
61 dogs with lymphosarcoma. Vet. Pathol. 31： 
528–540.
 13） HangaisHi, a., ogaWa, s., imamUra, n., miYaWaki, s., 
miUra, Y., Uike, n., sHimazaki, C., emi, n., takeYa-
ma, k., HirosaWa, s., kamada, n., kobaYasHi, Y., 
takemoto, Y., kitani, t., toYama, k., oHtake, s., 
Yazaki, Y., Ueda, r. and Hirai, H. 1996. Inactiva-
tion of multiple tumor-suppressor genes involved 
in negative regulation of the cell cycle, MTS1/
p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb 
genes in primary lymphoid malignancies. Blood 
87：4949–4958.
40
P16, P15, AND P14 GENE ABERRATIONS IN DOG
 14） Hara, e., smitH, r., ParrY, d., taHara, H., stone, s. 
and Peters, G. 1996. Regulation of p16CDKN2 ex-
pression and its implications for cell immortaliza-
tion and senescence. Mol. Cell. Biol. 16：859–867.
 15） Hiraoka, H., minami, k., kaneko, n., sHimokaWa mi-
Yama, t., okamUra, Y., mizUno, t. and okUda, M. 
2009. Aberrations of the FHIT gene and Fhit pro-
tein in canine lymphoma cell lines. J. Vet. Med. 
Sci. 71：769–777.
 16） HUtter, g., sCHeUbner, m., zimmermann, Y., kalla, j., 
katzenberger, t., HUbler, k., rotH, s., Hiddemann, 
W., ott, g. and dreYling, M. 2006. Differential ef-
fect of epigenetic alterations and genomic dele-
tions of CDK inhibitors ［p16（INK4a）, p15（INK4b）, 
p14（ARF）］ in mantle cell lymphoma. Genes Chro-
mosomes Cancer 45：203–210.
 17） jardin, F., jais, j. P., molina, t. j., Parmentier, F., 
PiCqUenot, j. m., rUminY, P., tillY, H., bastard, C., 
salles, g. a., FeUgier, P., tHieblemont, C., gissel-
breCHt, C., de reYnies, a., CoiFFier, b., HaioUn, C. 
and leroY, K. 2010. Diffuse large B-cell lymphomas 
with CDKN2A deletion have a distinct gene ex-
pression signature and a poor prognosis under 
R-CHOP treatment： a GELA study. Blood 116：
1092–1104.
 18） kees, U. r., terrY, P. a., Ford, j., everett, j., 
mUrCH, a., de klerk, n. and baker, D. L. 2005. De-
tection of hemizygous deletions in genomic DNA 
from leukaemia specimens for the diagnosis of pa-
tients. Leuk. Res. 29：165–171.
 19） kim, m., Yim, s. H., CHo, n. s., kang, s. H., ko, d. H., 
oH, b., kim, t. Y., min, H. j., sHe, C. j., kang, H. j., 
sHin, H. Y., aHn, H. s., Yoon, s. s., kim, b. k., sHin, 
H. r., Han, k. s., CHo, H. i. and lee, D. S. 2009. Ho-
mozygous deletion of CDKN2A （p16, p14） and 
CDKN2B （p15） genes is a poor prognostic factor 
in adult but not in childhood B-lineage acute lym-
phoblastic leukemia： a comparative deletion and 
hypermethylation study. Cancer Genet. Cytogenet. 
195：59–65.
 20） klangbY, U., okan, i., magnUsson, k. P., Wendland, 
m., lind, P. and Wiman, K. G. 1998. p16/INK4a and 
p15/INK4b gene methylation and absence of p16/
INK4a mRNA and protein expression in Burkitt’s 
lymphoma. Blood 91：1680–1687.
 21） koenig, a., bianCo, s. r., Fosmire, s., WojCieszYn, j. 
and modiano, J. F. 2002. Expression and signifi-
cance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN 
tumor suppressors in canine melanoma. Vet. 
Pathol. 39：458–472.
 22） koHno, t., Yamada, Y., taWara, m., takasaki, Y., 
kamiHira, s., tomonaga, m. and matsUYama, T. 
2007. Inactivation of p14ARF as a key event for 
the progression of adult T cell leukemia/lympho-
ma. Leuk. Res. 31：1625–1632.
 23） krUg, U., ganser, a. and koeFFler, H. P. 2002. Tu-
mor suppressor genes in normal and malignant 
hematopoiesis. Oncogene 21, 3475-3495.
 24） lee, s. m., lee, e. j., ko, Y. H., lee, s. H., maeng, l. 
and kim, K. M. 2009. Prognostic significance of 
O6-methylguanine DNA methyltransferase and 
p57 methylation in patients with diffuse large 
B-cell lymphomas. APMIS 117：87–94.
 25） li, j., Poi, m. j. and tsai, M. D. 2011. Regulatory 
mechanisms of tumor suppressor P16（INK4A） 
and their relevance to cancer. Biochemistry 50： 
5566–5582.
 26） masUmoto, n., FUjii, t., isHikaWa, m., saito, m., 
iWata, t., FUkUCHi, t., sUsUmU, n., mUkai, m., 
kUbUsHiro, k., tsUkazaki, k. and nozaWa, S. 2003. 
P16 overexpression and human papillomavirus in-
fection in small cell carcinoma of the uterine cer-
vix. Hum. Pathol. 34：778–783.
 27） modiano, j. F., breen, m., valli, v. e., WojCieszYn, j. 
W. and CUtter, G. R. 2007. Predictive value of p16 
or Rb inactivation in a model of naturally occur-
ring canine non-Hodgkin’s lymphoma. Leukemia 
21：184–187.
 28） momoi, Y., okai, Y., Watari, t., goitsUka, r., tsU-
jimoto, H. and HasegaWa, A. 1997. Establishment 
and characterization of a canine T-lymphoblastoid 
cell line derived from malignant lymphoma. Vet. 
Immunol. Immunopathol. 59：11–20.
 29） nakaiCHi, m., taUra, Y., kanki, m., mamba, k., mo-
moi, Y., tsUjimoto, H. and nakama, S. 1996. Estab-
lishment and characterization of a new canine 
B-cell leukemia cell line. J. Vet. Med. Sci. 58：469–
471.
 30） omUra-minamisaWa, m., diCCianni, m. b., batova, 
a., CHang, r. C., bridgeman, l. j., YU, j., PUllen, j., 
boWman, W. P. and YU, A. L. 2000. Universal inacti-
vation of both p16 and p15 but not downstream 
components is an essential event in the pathogen-
esis of T-cell acute lymphoblastic leukemia. Clin. 
Cancer Res. 6：1219–1228.
 31） ParrY, d., bates, s., mann, d. j. and Peters, G. 
1995. Lack of cyclin D-Cdk complexes in Rb-nega-
tive cells correlates with high levels of p16INK4/
MTS1 tumour suppressor gene product. EMBO J. 
14：503–511.
 32） Popov, N. and Gil, J. 2010. Epigenetic regulation of 
the INK4b-ARF-INK4a locus： in sickness and in 
health. Epigenetics 5：685–690.
 33） roman-gomez, j., jimenez-velasCo, a., Castillejo, j. 
41
日本獣医生命科学大学研究報告　第 62 号（2013）
a., agirre, x., barrios, m., navarro, g., molina, F. 
j., Calasanz, m. j., ProsPer, F., Heiniger, a. and 
torres, A. 2004. Promoter hypermethylation of 
cancer-related genes： a strong independent prog-
nostic factor in acute lymphoblastic leukemia. 
Blood 104：2492–2498.
 34） rUsso, a. a., tong, l., lee, j. o., jeFFreY, P. d. and 
PavletiCH, N. P. 1998. Structural basis for inhibi-
tion of the cyclin-dependent kinase Cdk6 by the 
tumour suppressor p16INK4a. Nature 395：237–
243.
 35） rUtgen, b. C., Hammer, s. e., gerner, W., CHristian, 
m., de aresPaCoCHaga, a. g., Willmann, m., kleit-
er, m., sCHWendenWein, i. and saalmUller, A. 2010. 
Establishment and characterization of a novel ca-
nine B-cell line derived from a spontaneously oc-
curring diffuse large cell lymphoma. Leuk. Res. 
34：932–938.
 36） serrano, m., lee, H., CHin, l., Cordon-Cardo, C., 
beaCH, d. and dePinHo, R. A. 1996. Role of the 
INK4a locus in tumor suppression and cell mortali-
ty. Cell 85, 27–37.
 37） sHiozaWa, e., takimoto, m., makino, r., adaCHi, d., 
saito, b., YamoCHi-onizUka, t., YamoCHi, t., sHimo-
zUma, j., maeda, t., koHno, Y., kaWakami, k., na-
kamaki, t., tomoYasU, s., sHiokaWa, a. and ota, H. 
2006. Hypermethylation of CpG islands in p16 as a 
prognostic factor for diffuse large B-cell lymphoma 
in a high-risk group. Leuk. Res. 30： 859–867.
 38） starrak, g. s., berrY, C. r., Page, r. l., joHnson, j. l. 
and tHrall, D. E. 1997. Correlation between tho-
racic radiographic changes and remission/survival 
duration in 270 dogs with lymphosarcoma. Vet Ra-
diol Ultrasound 38, 411–418.
 39） takasaki, Y., Yamada, Y., sUgaHara, k., HaYasHi, t., 
dateki, n., HarasaWa, H., kaWabata, s., soda, H., 
ikeda, s., tomonaga, m. and kamiHira, S. 2003. In-
terruption of p16 gene expression in adult T-cell 
leukaemia/lymphoma： clinical correlation. Br. J. 
Haematol. 122：253–259.
 40） tanigUCHi, t., CHikatsU, n., takaHasHi, s., FUjita, a., 
UCHimarU, k., asano, s., FUjita, t. and motokUra, 
T. 1999. Expression of p16INK4A and p14ARF in 
hematological malignancies. Leukemia 13：1760–
1769.
 41） tHomas, r., seiser, e. l., motsinger-reiF, a., borst, 
l., valli, v. e., kelleY, k., sUter, s. e., argYle, d., 
bUrgess, k., bell, j., lindblad-toH, k., modiano, j. 
F. and breen, M. 2011. Refining tumor-associated 
aneuploidy through ‘genomic recoding’ of recur-
rent DNA copy number aberrations in 150 canine 
non-Hodgkin lymphomas. Leuk. Lymphoma 52：
1321–1335.
 42） valli, v. e., vernaU, W., de lorimier, l. P., gra-
Ham, P. s. and moore, P. F. 2006. Canine indolent 
nodular lymphoma. Vet. Pathol. 43：241–256.
 43） Wong, i. H., ng, m. H., HUang, d. P. and lee, J. C. 
2000. Aberrant p15 promoter methylation in adult 
and childhood acute leukemias of nearly all mor-
phologic subtypes： potential prognostic implica-
tions. Blood 95：1942–1949.
 44） Yamazaki, j., baba, k., goto-kosHino, Y., setogU-
CHi-mUkai, a., FUjino, Y., oHno, k. and tsUjimoto, 
H. 2008. Quantitative assessment of minimal resid-
ual disease （MRD） in canine lymphoma by using 
real-time polymerase chain reaction. Vet. Immu-
nol. Immunopathol. 126：321–331.
 45） zainUddin, n., kandUri, m., berglUnd, m., lindell, 
m., amini, r. m., roos, g., sUndstrom, C., enblad, g. 
and rosenqUist, R. 2010. Quantitative evaluation of 
p16（INK4a） promoter methylation using pyrose-
quencing in de novo diffuse large B-cell lymphoma. 
Leuk. Res. 35：438–443.
 46） zindY, F., qUelle, d. e., roUssel, m. F. and sHerr, C. 
J. 1997. Expression of the p16INK4a tumor sup-
pressor versus other INK4 family members during 
mouse development and aging. Oncogene 15：203–
211.
　
42
